Choroid Plexus Tumor Drug Discovery Service

Choroid plexus tumors are rare primary epithelial brain tumors arising in the ventricle, which are characterized by nuclear pleomorphism, blurring of the papillary pattern, necrosis, and high nucleus-to-cytoplasm ratios. It has been classified into 3 histological grades, namely more benign choroid plexus papilloma (CPP), aggressive choroid plexus carcinoma (CPC), and atypical choroid plexus papilloma (aCPP). Although they can be surgically removed, choroid plexus tumors usually spread along the neuraxis and recur after operation and treatment.

Due to the scarcity of study populations, the tumorigenesis and the best treatment regimen for choroid plexus tumors remain undefined. Creative Biolabs has accumulated years of experience and integrated global resources in the field of neuroscience. Our one-stop solutions for choroid plexus tumors allow researchers and developers to investigate the pathogenesis of choroid plexus tumors, and thus develop promising therapies.

Mechanism of Action Studies of Choroid Plexus Tumor

The MoA studies of choroid plexus tumors remain undetermined. Genetic alterations are involved in the pathogenesis of children and adult choroid plexus tumors including, frequent numerical aneuploidy, TP53 tumor suppressor gene alterations, TERT promoter mutations, DNA methylation in AK1, PER2, and PLSCR4, the gain of chromosome 5, and a novel CCDC47-PRKCA gene fusion (Pienkowska, 2019; Thomas, 2021). Gamma-aminobutyric acid (GABA) is a tumor-signaling molecule in the central and peripheral nervous systems. GABA together with its receptors is involved in tumor cell proliferation in choroid plexus tumors. The alteration of circadian rhythms potentially leads to increased susceptibility to cancer in humans. It has been investigated that GABA regulation and AMP-activated protein kinase (AMPK) are important in circadian rhythms. In addition, c-MYC overexpression induces CPP through a T-cell-mediated inflammatory mechanism (Merve, 2019). The MoA studies of choroid plexus tumors remain undetermined. Scientists at Creative Biolabs are dedicated to providing you with choroid plexus tumor expertise and help to explore the underlying mechanisms for further drug discovery.

Fig.1 Management of patients with newly diagnosed choroid plexus carcinoma. (Tabori, 2010)

Choroid Plexus Tumor Solutions at Creative Biolabs

Although surgery, radiotherapy, and chemotherapy are the preferred traditional treatment for choroid plexus tumors, Creative Biolabs is committed to offering one-stop solutions for choroid plexus tumor studies to develop novel chemotherapy, targeted therapy, or immunotherapy according to the patient's condition and the progression of the disease. Besides, we also offer development services to develop anti-inflammatory agents for benign choroid plexus tumors expressing c-MYC (Merve, 2019). With years of experience in neuroscience and advanced technologies, Creative Biolabs provides a full range of services, including but not limited to discovery services, in vitro, in vivo, and ex vivo services. Stable cell cultures and high-fidelity mouse models of p53-deficient malignant choroid plexus tumors are available. Our platforms are equipped with latest scientific technologies. Our professionals strive to offer you dependable data and guidance to assist you move forward in your research programs. You can learn more about our platforms for choroid plexus tumor translational research with the following scheme.

If you have the intention to learn more about preclinical choroid plexus tumor drug discovery solutions, contact us for more information.

References

1. Pienkowska, M.; et al. DNA methylation signature is prognostic of choroid plexus tumor aggressiveness. Clinical epigenetics. 2019, 11(1): 1-16.
2. Thomas, C.; et al. The genetic landscape of choroid plexus tumors in children and adults. Neuro-oncology. 2021, 23(4): 650-660.
3. Merve, A.; et al. c-MYC overexpression induces choroid plexus papillomas through a T-cell mediated inflammatory mechanism. Acta neuropathologica communications. 2019, 7(1): 1-18.
4. Tabori, U.; et al. TP53 alterations determine clinical subgroups and survival of patients with choroid plexus tumors. Journal of clinical oncology. 2010, 28(12): 1995-2001.